Clinical Trial

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Objective of this study to evaluate 1-year disease-free survival in patients with dMMR/MSI-H or POLE/POLD1 gene mutations with gastric or esophagus-gastric junctional adenocarcinoma or colorectal adenocarcinoma after chemotherapy-sequential tiralizumab adjuvant radical resection (based on RECIST v1.1 criteria).
Trial Details
NCT Number NCT06118658
Lead Sponsor China Medical University, China
Conditions Gastric, Colorectal Adenocarcinoma
Enrollment 30 participants
Start Date 2023-11-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-07